
    
      Alogliptin is a selective and potent dipeptidyl peptidase-4 inhibitor developed by Takeda for
      use in patients with type 2 diabetes mellitus.

      Cardiovascular outcomes is of special interest in the type 2 diabetes mellitus population,
      particularly in type 2 diabetes mellitus patients who have cardiovascular disease and are at
      high risk for major adverse cardiac events, such as those patients who have had recent acute
      coronary syndrome.

      This study has been designed to evaluate the cardiovascular safety of alogliptin versus
      placebo in addition to Standard of Care in adults with type 2 diabetes mellitus and acute
      coronary syndrome.
    
  